Moderna Inc (NASDAQ:MRNA) price on Thursday, February 27, fall -7.42% below its previous day’s close as a downside momentum from buyers pushed the stock’s value to $31.09.
A look at the stock’s price movement, the close in the last trading session was $33.58. Turning to its 52-week performance, $170.47 and $29.25 were the 52-week high and 52-week low respectively. Overall, MRNA moved -30.82% over the past month.
Moderna Inc’s market cap currently stands at around $12.00 billion, with investors looking forward to this quarter’s earnings report slated for in March.
Analysts have a consensus estimate of 134.46M for the company’s revenue for the quarter, with a low and high estimate of 93.9M and 183M respectively. The average forecast suggests down to a -19.48% growth in sales growth compared to quarterly growth in the same period last fiscal year. Wall Street analysts have also projected the company’s year-on-year revenue to grow to 2.14B, representing a -33.96% decline on that reported in the last financial year.
Turning to the stock’s technical picture we see that short term indicators suggest on average that MRNA is a 100% Sell. On the other hand, the stock is on average a 100% Sell as suggested by medium term indicators while long term indicators are putting the stock in 100% Sell category.
17 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 3 analyst(s) rate the stock as a Hold, 12 recommend MRNA as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 2 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
MRNA’s current price about -9.01% and -17.48% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 39.11, while 7-day volatility ratio is 6.18% and 7.28% in the 30-day chart. Further, Moderna Inc (MRNA) has a beta value of 1.85, and an average true range (ATR) of 2.71. Analysts have given the company’s stock an average 52-week price target of $63.5, forecast between a low of $45 and high of $238. Looking at the price targets, the low is -44.74% off current price level while to achieve the yearly target high, price needs to move -665.52%. Nonetheless, investors will most likely welcome a -104.25% jump to $63.5 which is the analysts’ median price.
If we refocus on Moderna Inc (NASDAQ:MRNA), historical trading data shows that trading volumes averaged 10.81 million over the past 3 months. The company’s latest data on shares outstanding shows there are 386.00 million shares.
The 11.42% of Moderna Inc’s shares are in the hands of company insiders while institutional holders own 70.65% of the company’s shares. Current price change has pushed the stock -25.23% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the MRNA stock continues to rise going into the next quarter.
